Hospital
Medical University Hospital Authority
Medical University Hospital Authority was paid $8.51M by Medicaid between Mar 2019 and Dec 2024, across 185 billing codes. Its largest line is 80053, Comprehensive metabolic panel — 16% of everything it billed.
33Billing provider infoMEDICAL UNIVERSITY HOSPITAL AUTHORITY
MULLINS, SC 29574
MULLINS, SC 29574
33aNPI1447723945assigned 01/07/2019
33bProvider typeGeneral Acute Care Hospital
28Total paid$8.51M
24GClaims313,245
24DCodes billed185
24AFirst – last monthMar 2019 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in South Carolina
Rank by total paid#37 of 115
Median peer was paid$2.47M
This provider vs. median3.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RAE, KARYN controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 51,392 | $1.38M | |
| 2020 | 41,154 | $1.09M | |
| 2021 | 46,806 | $1.27M | |
| 2022 | 66,075 | $1.66M | |
| 2023 | 59,419 | $1.77M | |
| 2024incomplete | 48,399 | $1.34M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80053 | Comprehensive metabolic panel | 16% | 16,247 | 14,408 | $1.35M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 13% | 8,547 | 8,065 | $1.08M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 6.9% | 4,399 | 4,230 | $583K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 5.1% | 3,783 | 2,957 | $432K |
| 80048 | Basic metabolic panel (calcium, ionized) | 4.7% | 6,135 | 5,168 | $397K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.3% | 7,727 | 2,256 | $364K |
| 36415 | Collection of venous blood by venipuncture | 4.0% | 18,086 | 15,037 | $342K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.9% | 19,445 | 17,894 | $334K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.7% | 4,492 | 4,249 | $312K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.8% | 2,239 | 2,168 | $238K |
| 81001 | 2.2% | 11,577 | 10,661 | $191K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.2% | 1,653 | 1,547 | $187K |
173 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.1% | 6,184 | $177K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.7% | 4,604 | $143K |
| 11043 | 1.5% | 471 | $124K | |
| 99284 | Emergency room visit (serious) | 1.4% | 14,862 | $115K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.3% | 4,966 | $114K |
| 77063 | Screening digital breast tomosynthesis, bilateral | 1.1% | 871 | $94K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.1% | 1,479 | $93K |
| 81003 | 1.1% | 3,984 | $90K | |
| 81025 | 1.0% | 6,925 | $89K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,721 | $82K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 617 | $77K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,804 | $77K |
| 82947 | <1% | 2,381 | $72K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,663 | $70K |
| 87077 | <1% | 1,945 | $70K | |
| 71045 | Radiologic examination, chest; single view | <1% | 7,514 | $61K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,318 | $57K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 312 | $53K |
| 87070 | <1% | 570 | $50K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,389 | $50K |
| 73630 | <1% | 890 | $46K | |
| 87081 | <1% | 610 | $44K | |
| 73562 | <1% | 1,205 | $41K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 16,614 | $41K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,172 | $40K |
| 73610 | <1% | 697 | $36K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 480 | $32K |
| 73030 | <1% | 799 | $32K | |
| 73130 | <1% | 528 | $31K | |
| 97161 | <1% | 1,055 | $28K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,371 | $26K |
| 99285 | Emergency room visit (most serious) | <1% | 5,384 | $26K |
| 86900 | <1% | 164 | $26K | |
| 87807 | <1% | 400 | $24K | |
| 80061 | Lipid panel | <1% | 2,640 | $23K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,165 | $22K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 826 | $22K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,639 | $22K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 99 | $21K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,404 | $20K |
| 74018 | <1% | 572 | $17K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,747 | $17K |
| 0002A | <1% | 274 | $15K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,930 | $13K |
| 86710 | <1% | 287 | $13K | |
| 72100 | <1% | 351 | $12K | |
| 76770 | <1% | 150 | $12K | |
| 0001A | <1% | 220 | $12K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 887 | $11K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 156 | $11K |
| 84702 | <1% | 350 | $11K | |
| 84439 | <1% | 1,416 | $10K | |
| 82962 | <1% | 396 | $9K | |
| 87210 | <1% | 227 | $9K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,054 | $9K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,536 | $7K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,004 | $7K |
| 85610 | <1% | 2,769 | $6K | |
| 93017 | <1% | 390 | $6K | |
| 73110 | <1% | 124 | $6K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 253 | $6K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,624 | $6K |
| 85027 | <1% | 5,047 | $5K | |
| 76830 | Ultrasound, transvaginal | <1% | 37 | $5K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,114 | $5K |
| 87186 | <1% | 1,437 | $5K | |
| 93971 | <1% | 39 | $5K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,522 | $5K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 26 | $4K |
| G0378 | Hospital observation service, per hour | <1% | 1,478 | $4K |
| 84484 | <1% | 6,361 | $4K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 49 | $4K |
| 0072A | <1% | 62 | $3K | |
| 72110 | <1% | 52 | $3K | |
| 96376 | <1% | 464 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,182 | $3K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 25 | $3K |
| 73502 | <1% | 127 | $3K | |
| 85379 | <1% | 735 | $3K | |
| 86901 | <1% | 164 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 794 | $3K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,993 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,494 | $2K |
| 83880 | <1% | 2,733 | $2K | |
| 15271 | <1% | 28 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 290 | $2K |
| 71250 | <1% | 31 | $2K | |
| 0003A | <1% | 35 | $2K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,413 | $2K |
| 83605 | <1% | 2,223 | $2K | |
| 73560 | <1% | 46 | $2K | |
| 87899 | <1% | 110 | $1K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 38 | $1K |
| 80320 | <1% | 1,002 | $1K | |
| 88304 | <1% | 14 | $1K | |
| 0071A | <1% | 25 | $1K | |
| 86803 | <1% | 32 | $1K | |
| 83655 | <1% | 55 | $1K | |
| 80076 | <1% | 81 | $1K | |
| 83735 | <1% | 4,194 | $1K | |
| 73080 | <1% | 13 | $947.48 | |
| 76801 | <1% | 28 | $901.35 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 263 | $897.52 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 263 | $796.48 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 152 | $789.36 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 27 | $655.10 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 100 | $646.54 |
| 76642 | <1% | 14 | $615.63 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 375 | $558.00 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 41 | $469.92 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,377 | $449.98 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 311 | $440.36 |
| 72040 | <1% | 17 | $415.95 | |
| 87040 | <1% | 2,057 | $412.50 | |
| 82728 | <1% | 73 | $407.75 | |
| 83690 | <1% | 3,615 | $382.21 | |
| 29581 | <1% | 71 | $364.27 | |
| 87430 | <1% | 176 | $352.33 | |
| 82570 | <1% | 211 | $258.84 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 13 | $229.50 |
| 86140 | <1% | 186 | $226.24 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 15 | $95.74 |
| 36600 | <1% | 205 | $56.27 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 133 | $49.32 |
| 85018 | <1% | 98 | $43.54 | |
| 94644 | <1% | 204 | $40.22 | |
| 82805 | <1% | 217 | $25.30 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 762 | $25.26 |
| 82043 | <1% | 112 | $23.18 | |
| 97162 | <1% | 12 | $15.98 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,348 | $5.78 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 650 | $3.73 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,289 | $1.67 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,248 | $0.09 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 972 | $0.00 |
| 80143 | 0% | 56 | $0.00 | |
| 85007 | 0% | 54 | $0.00 | |
| 90714 | 0% | 86 | $0.00 | |
| 90715 | 0% | 46 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 116 | $0.00 |
| 83540 | 0% | 44 | $0.00 | |
| 82248 | 0% | 112 | $0.00 | |
| 84100 | 0% | 14 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 110 | $0.00 |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 0% | 16 | $0.00 |
| 80179 | 0% | 28 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 34 | $0.00 |
| 51702 | 0% | 15 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 25 | $0.00 |
| 31720 | 0% | 22 | $0.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 260 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 1,958 | $0.00 |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 0% | 404 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 969 | $0.00 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | 0% | 92 | $0.00 |
| 85730 | 0% | 1,612 | $0.00 | |
| 82077 | 0% | 498 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 87 | $0.00 |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 0% | 91 | $0.00 |
| 87205 | 0% | 93 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 185 | $0.00 |
| 82550 | 0% | 190 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 461 | $0.00 |
| 83550 | 0% | 28 | $0.00 | |
| 82553 | 0% | 110 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 29 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 69 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 109 | $0.00 |
| 88342 | 0% | 25 | $0.00 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 166 | $0.00 |
| 82803 | 0% | 14 | $0.00 | |
| 85652 | 0% | 31 | $0.00 | |
| 85651 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRAE, KARYN (DIRECTOR)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.